Preparation method of swainsonine derivatives and scientific research reagents thereof

Abstract

The invention provides a swainsonine derivative and a preparation method of a research reagent of the swainsonine derivative. The swainsonine is prepared through the following synthesis steps: a, adding chloroacetic acid and potassium hydroxide by taking swainsonine as a raw material and taking water as a solvent; b, feeding hematoporphyrin into thionyl chloride, and then adding cordycepin; and c, pouring the product obtained in the step a into the product obtained in the step b, and dropwise adding newly prepared potassium ethoxide into the obtained mixture, so that a swainsonine derivative solution is obtained. The swainsonine derivative disclosed by the invention is a product derived on the basis of a swainsonine structure, and by comparing, the difference is as follows: an enriched heterocyclic ring is connected, so that the swainsonine derivative disclosed by the invention has a function of enriching cancer cells, and can allow drugs to tend to parts with tumors but allow the drug concentration of other parts to be little.

Description

technical field [0001] The invention belongs to chemical synthesis technology, in particular to a swainsonine derivative. Background technique [0002] 1. The key to cancer metastasis outside the membrane is the adhesion of sialic acid [0003] Cancer is a large class of diseases characterized by abnormal cell proliferation and metastasis. More than 90% of cancer patients die from cancer metastasis. [0004] Studies have shown that cancer is a mixture of dozens or even hundreds of diseases with heterogeneous characteristics. Although cancer is quite complex, the development of cancer has a common feature: elevated sialic acid in patients. The end of the oligosaccharide chain on the surface of tumor cells is sialic acid, and the increase of the branch of sialic acid is the key link of adhesion, and it is an important reason for the shedding and adhesion of cancer cells in the process of metastasis! The present invention thinks that the behavior of cancer metastasis mainly ...

AI Technical Summary

Problems solved by technology

[0013] At present, the problem with swainsonine is that domestic and foreign animal and clinical tests have proved that if the swainsonin solution exceeds a certain concentration, it will produce toxicity, and it must be limited to the specified concentration.

[0019] However, swainsonine is currently undergoing Phase III clinical trials abroad. Although the anti-cancer efficacy is basically positive, it is still in a difficult state of drug concentration, drug resistance and targeted drugs, and the connection of porphyrin rings has not yet been carried out.

Images